# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2012 Earnings Results

**Report date:** 2012-04-26 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2012

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 9.04%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.37 | N/A | +282.27% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized the importance of continuing to deliver value to patients.

**Key quotes:**

> We are pleased with our performance this quarter, especially in EPS.

> Our focus remains on innovation and delivering value to patients.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance significantly exceeded expectations, leading to a notable stock increase of 9.04%. Investors reacted positively, likely due to the surprise in earnings despite the lack of revenue data. The management's focus on innovation and patient value suggests a strategic direction that could benefit the company in the long term.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2012_